Shareholders have rejected Florenz’s takeover offer, and Bougen is still talking of putting a recapitalisation plan before the board.
The ASX-listed company is guiding ebitda break-even for the first time in 2024.
Supie chair and major shareholder come out swinging in defence of CEO and founder Sarah Balle as company hits capital roadblock.
Listed insurer talks up resilience as catastrophic weather dampens profit.
The cancer diagnostics company still has overhang of decision on Medicare coverage in the US.
The NZX-listed hospitality operator has never paid one out to shareholders.
The company has put emphasis on cash flow reporting but it’s not transparent enough for one analyst.
Manufacturer still seeing lasting effects of customers' inventory stockpiling.
Telematics provider has reaffirmed its goal of being free cashflow neutral by FY25, and positive the year after.
Exports volumes down as surrounding industries and infrastructure continue to repair – second half will also be affected, it says.